sarcoidosis

Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmonary fibrosis, pulmonary hypertension (PAH), and respiratory failure caused by SARS-CoV-2.

CSLP43 is a selective inhibitor of RIPK2 and XIAP, presenting an IC50 of 19.9 nM for human RIPK2. It binds to the ATP binding pocket of RIPK2, disrupting interactions with the XIAPBIR2 or cIAP1BIR2 domains. CSLP43 effectively inhibits RIPK2 ubiquitination, NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. It specifically targets NOD1/NOD2 signaling pathways without affecting the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable in research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease.

PD-360324 is a human monoclonal antibody (mAb) that targets CSF1/M-CSF. It can be utilized in research related to skin lupus, pulmonary sarcoidosis, and rheumatoid arthritis.